Day 1 - Wednesday, 7 December 2016
Topics
Meeting category
Date(s)
7 Dec 2016 - 9 Dec 2016
Location
Cabo,
Mexico
Platinum Level Support
Sponsor logos
HIV DART and Emerging Viruses 2016
Related Enduring Materials
Enduring Materials
Opening Session -
Presentation of David Barry DART Achievement Award
Session 1: Cure Session (Sponsored by amfAR) -
Chairs
Rowena Johnston, PhD
amfAR, USA
Controversies and Misconceptions in HIV Reservoir Research
Mario Stevenson, PhD
University of Miami/GVN, USA
Humanized Mice as Models in Drug Development for Antiviral Therapies
J. Victor Garcia-Martinez, PhD
University of North Carolina, USA
Sustained Virologic Control in SIV+ Macaques
Siddappa Byrareddy, PhD
University of Nebraska Medical Center, USA
Differential responses of memory CD4+ T cell subsets to HIV latency reversing agents
HIV-1 dynamics under integrase inhibitor therapy suggests a subset of cells with slow integration
Session 2: New Drugs for HIV -
Chairs
Baek Kim, PhD
Emory University, USA
Ronald Desrosiers, PhD
University of Miami, USA
State of the Art Lecture: Integrase Inhibitors Today and Tomorrow
Jay Grobler, PhD
Merck Inc., USA
Development of a New Class of Allosteric Inhibitors of HIV-1 Integrase with Promising Activity Against Resistance Mutations
Eddy Arnold, PhD
Rutgers University, USA
CryoEM Structures and Atomic Model of the HIV-1 Strand Transfer Complex Intasome
Dmitry Lyumkis, PhD
Salk Institute, USA
Session 3: Inflammation and Cure -
Chairs
Mario Stevenson, PhD
University of Miami, USA
David Thomas, MD
Johns Hopkins School of Medicine, USA
Current Clinical Therapies for HIV Remission
Impact of Jak Inhibitors on HIV Reservoir Maintenance, Lifespan and Expansion in Primary T Cells and Macrophages
Anti–HIV drug candidate abx464 prevents intestinal inflammation by producing IL22 in activated macrophages
Cure and Controversies Debate
Day 2 - Thursday, 8 December 2016
-
Chairs
Rowena Johnston, PhD
amfAR, USA
Presentation of Gertrude Elion Distinguished Lecturer Award
Rowena Johnston, PhD
amfAR, USA
Gertrude Elion Distinguished Lecturer Award Lecture Stories on Scientific Discoveries that Transformed HIV into a Manageable Disease
Session 4: New Drugs and NeuroAIDS -
Chairs
Ladislau Kovari
Wayne State University, USA
Management of Neurocognitive Impairment of Aging Populations Living with HIV
EFdA (4'-Ethynyl-2-fluoro-2'-deoxyadenosine) a Powerful Nucleoside Analog for HIV Infections
Development of a protease inhibitor-based single-tablet complete HIV-1 regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (DCFTAF)
Antiviral Activity of tenofovir alafenamide against HIV-1 with thymidine analog mutation(s) and M184V
Session 5: Co-infections, Immunology and Public Health -
Chairs
Eddy Arnold
Rutgers University, USA
AAV Vector to Deliver Potent Broadly Neutralizing Antibody for Treatment Purpose
Ronald Desrosiers, PhD
University of Miami, USA
State of the Art Lecture: Phylogenetics and Intervention Strategies
Richard Harrigan, PhD
British Columbia Centre for Excellence in HIV, Canada
Predicting Antiviral Drug Toxicity Using Contractility Analysis Of Human IPSC Derived Cardiomyocytes
Day 3 - Friday, 9 December 2016
Session 6: Emerging Viruses I: Epidemiology, Pathogenesis & Treatmen -
Chairs
Insights into Viral Pathogenesis and Antiviral Strategies for Zika
Alan Perelson, PhD
Los Alamos, USA
In Silico Approaches Towards Broadly Active Flavivirus Protease Inhibitors
Jak 1/2 Inhibition Modulates Production of Replication Competent Zika Virus in Primary Human Hofbauer, Trophoblast and Neuroblastoma Cells
Leda Bassit, Emory University, USA
O_07
Session 7: Emerging Viruses II: Diagnosis and Treatment -
Chairs
Oscar Perng, PhD
National Cheng Kung University, Taiwan
Alan Perelson, PhD
Los Alamos, USA
State of the Art Lecture: Research efforts to combat ZIKA: The Miami experience
David Watkins
University of Miami, USA
Zika-Specific Antibodies for Prophylaxis and Detection
David Watkins
University of Miami, USA
Rapid Zika Detection for Resource-Limited Regions
Overview
Welcome
Thank you to all Faculty members and delegates who participated in this year's HIV DART & Emerging Viruses, held from 7-9 December!
We look back at a very successful meeting with key speakers, exciting lectures, and great oral abstract presentations. All this at a beautiful location: Los Cabos, Mexico! We hope you enjoyed the meeting as much as we did.
We would like to thank our sponsors once more, as this meeting would not have been possible without them: Gilead, the Raymond F. Schinazi & Family Foundation, and ST Pharm Co. Ltd. Thank you to our meeting partners: amfAR, Emory University, Erasmus Medical Center, and Global Virus Network. Your support has been invaluable.
Again, we thank you for your contribution and attendance.
The Program Chairs,
Chairs
Support
Platinum Level
Gold Level
RFS & Family Foundation
HIV DART & Emerging Viruses is proud to partner with the below institutions.
Language
Sorry… This form is closed to new submissions.